# Empagliflozin + Linagliptin

## Glyxambi 25/5mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OGXB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Indications        | Type 2 diabetes mellitus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Dosing             | Initial empagliflozin 10 mg/linagliptin 5 mg orally once daily in the morning， may increase to empagliflozin 25 mg/linagliptin 5 mg once daily if tolerated.                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Severe renal impairment， dialysis， or end-stage renal disease. Hypersensitivity reaction to empagliflozin， linagliptin， or any of the excipients; anaphylaxis， angioedema， exfoliative skin conditions， urticaria， or bronchial hyperreactivity have occurred.                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Common Renal: Urinary tract infectious disease (11.4% to 12.5% ) Respiratory: Nasopharyngitis (5.9% to 6.6% )， Upper respiratory infection (7% ) Serious Cardiovascular: Heart failure， Hypotension Endocrine metabolic: Diabetic ketoacidosis， Hypoglycemia (2.2% to 3.6% ) Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Musculoskeletal: Arthralgia Renal: Creatinine clearance-glomerular filtration abnormal， Decreased， Pyelonephritis， Sepsis due to urinary tract infection， Serum creatinine raised Reproductive: Necrotizing fasciitis， Perineum Other: Angioedema |
| Pregnancy          | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

